Asta Medica, Aktiengesellschaft

Zentaris Gmbh

Cytec Industries Inc.

Zentraris Gmbh

Algiax Pharmaceuticals Gmbh

Æterna Zentaris Gmbh

Matthias Rischer

Werner Sarlikiotis

Karl-Friedrich Landgraf

Bernhard Kutscher

Helmut Hettche

Alfred Olbrich

Juergen Engel

Peter Meisel

Karl Werner

Horst Mueller

Wilfried Thiel

Thomas Beisswenger

Jürgen Engel

Gunter Laban

Horst Bauer

Guido Koopmans

Birgit Hasse

Dominique Di Stefano

Eberhard Oestreich

Eric Saly

Maureen Mackay

J&uuml;rgen Sch&auml;fer

Wolfgang Mohr

Lena Kurz

Frank Güthlein

Lena Liebich

Ansgar Bögershausen

Sandra Kneisel

Martin Hagedorn

Horst Müller

A particulate solid composition comprises a blend of dialkyl sulfosuccinate and a water-soluble polymer. The water-soluble polymer can be a cellulose ether, a polysaccharide, a polyvinyl alcohol homopolymer or copolymer, a polyvinyl pyrrolidone homopolymer or copolymer, a polyvinyl caprolactam polymer or copolymer, a poly(meth)acrylate, a poly(alkylene oxide) graft copolymer, or a combination thereof. The particulate solid composition is free flowing, water-soluble, and dissolves rapidly in water. It can be made by drying a solution of dialkyl sulfosuccinate and a water-soluble polymer. The particulate solid composition can be mixed with organic substances having low water solubility, for example a generic, a biologic, a biosimilar, an excipient, a nutraceutical, a medical diagnostic agent, an agricultural chemical, or a combination thereof, to form water-soluble compositions.

Dialkyl sulfosuccinate compositions, method of making, and method of use

The invention provides sterile suspensions and sterile lyophilizates of slightly soluble basic peptide complexes, and pharmaceutical formulations comprising them. The provided sterile suspensions, sterile lyophilizates and pharmaceutical formulations comprising them are particularly suitable for use in a parenteral dosage form as medicaments for the treatment and prophylaxis of diseases and pathological states in mammals, especially in humans.

Sterile suspensions of slightly soluble basic peptide complexes and pharmaceutical formulations containing them

The present invention provides a novel process for producing sterile suspensions of slightly soluble basic peptide complexes. The present invention further provides a novel process for producing sterile lyophilizates of slightly soluble basic peptide complexes. In addition, a novel process for producing sterile suspensions suitable for the parenteral administration of slightly soluble basic peptide complexes is provided. The invention moreover provides sterile suspensions and sterile lyophilizates of slightly soluble basic peptide complexes, and pharmaceutical formulations comprising them. The provided sterile suspensions, sterile lyophilizates and pharmaceutical formulations comprising them are particularly suitable for use in a parenteral dosage form as medicaments for the treatment and prophylaxis of diseases and pathological states in mammals, especially in humans.

Process for producing sterile suspensions of slightly soluble basic peptide complexes, sterile suspensions of slightly soluble basic peptide complexes, pharmaceutical formulations containing them, and the use thereof as medicaments

An aqueous injectable soution of an LHRH antagonist, such as Cetrorelix, in an organic, pharmaceutically acceptable acid, such as gluconic acid.

Injectable solution of an LHRH antagonist

Modifications of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene, and processes for their preparation

Novel, advantageous dosage forms of thioctic acid and the enantiomers thereof together with thioctic acid salts are described. The pharmaceutical formulations according to the invention are used for the production of pharmaceutical dosage forms which release the active ingredient more rapidly and have greater bioavailability than previous forms.

Dosage forms containing thioctic acid or solid salts of thioctic acid with improved release and bioavailability

The invention is relative to a thioctic acid with a predominant amount of an enantiomer and a novel modification, in the case of which the X-ray powder diffractograms show a characteristic reflex in the range of 23.4 to 22.7.degree. 2 theta(Cu) which shifts in the direction of the smaller angular values as the enantiomer content increases.

Alpha-lipoic acid with novel modification

Dosage forms containing thioctic acid or solid salts of thioctic acid

The invention relates to novel modifications of the compound 2-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene of the formula I ##STR1## processes for their preparation and their use in pharmaceutical compositions.

Modifications of

Growing community of inventors

Frankfurt-am-Main, Germany

Matthias Rischer